Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ImmunoVEX HSV2
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**ImmunoVEX HSV2** is a live-attenuated herpes simplex virus type 2 (HSV-2) vaccine candidate rationally engineered by deleting key immune evasion genes, including ICP47, vhs (virion host shutoff protein), γ34.5, US5 (glycoprotein J), and UL43. Developed initially by BioVex (subsequently acquired by Amgen), it aims to prevent genital herpes by eliciting robust antiviral immunity while preventing viral immune suppression and replication in neurons. Preclinical studies in animal models demonstrated complete prevention of genital herpes symptoms and strong immune responses, with early Phase I clinical trials initiated in the UK around 2010 to assess safety and immunogenicity in humans.[1][5][7][10][12]
- Other names
- ImmunoVEX^HSV2^
02
Targets
NECTIN1 (Poliovirus receptor-related 1)C3b (Complement Component 3b)IgG Fc (Immunoglobulin G Fc region)TMEFF2
Beyond the preview
Go deeper on ImmunoVEX HSV2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunoVEX HSV2.